Dog /

Breed profile · FDA CVM July 2026 extract

Great Pyrenees adverse-event record

Adverse-event filings for Great Pyrenees (Dog) in the FDA Center for Veterinary Medicine openFDA extract. Browse dog breeds, reactions, and outcomes below.

#45 of 510
by report volume (all breeds)
4,513
FDA CVM reports on file
3.8%
death-coded share of reports
#188 of 275
by death-coded share (≥50 reports)

How the 4,513 reports break down

By recorded gender -- every report on file for Great Pyrenees, no filtering.

Annual report volume

Annual adverse-event report trend Yearly FDA CVM adverse-event report counts for this breed. 489 366.75 244.5 122.25 0 2019 2020 2021 2022 2023 2024 2025 2026 Reports filed Death-coded reports
Annual report volume for Great Pyrenees drawn from FDA CVM filings.

Data updated September 2026

The verdict

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Great Pyrenees ranks #45 of 510 by total reports (4,513) and #188 of 275 by death-coded share (3.8%). National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).

93,675
Retriever - Labrador reports (#1)
99.0%
Atlantic Salmon (Salmo salar) death share (#1)
#45
This breed, reports of 510
#188
This breed, death share of 275

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Great Pyrenees has 4,513 reports now versus 4,415 in that prior snapshot: 98 more (2.2%).

Report change
+98
Death-coded reports
+2
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Great Pyrenees changes

Total Reports

4,513

Highest-reported breed

Deaths Reported

170

of 4,513 reports

Death-coded share of reports

3.8%

Below-median death-coded share

Avg Age at Report

3.8 yr

39.7 kg avg weight

Breed Safety Scorecard

C- (52/100)

A weighted composite across 4 of 4 dimensions, each benchmarked against every tracked breed with at least 200 reports (n=185). Dimensions with insufficient data drop out and their weight redistributes to the rest, so a missing input never silently deflates the score.

Death rate B
3.8%

Share of reports coded as a fatality

Euthanasia rate B
1.7%

Share of reports resulting in euthanasia

Full recovery rate F
20.8%

Share of reports coded "Recovered/Normal"

5-year trend F
+21%

Change in annual report volume over the last 5 complete years

Death-Coded Outcome Share

Great Pyrenees death-coded reports 3.8%
Cross-breed median

3.8% of 4,513 great pyrenees reports involved a death outcome.

How to read this number

Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.

Where Great Pyrenees's death-coded share sits among indexed breeds

Death-coded share of FDA CVM reports, breeds with ≥50 reports (July 2026 extract)

4% 32nd percentile Higher share than 32% of 275 indexed breeds

5%–10%: 1 indexed breeds (0%). This entry sits in this band. 20%–25%: 2 indexed breeds (1%). Above this entry. 25%–30%: 3 indexed breeds (1%). Above this entry. 30%–35%: 4 indexed breeds (1%). Above this entry. 35%–40%: 5 indexed breeds (2%). Above this entry. 40%–45%: 6 indexed breeds (2%). Above this entry. 45%–50%: 3 indexed breeds (1%). Above this entry. 50%–55%: 7 indexed breeds (3%). Above this entry. 55%–60%: 7 indexed breeds (3%). Above this entry. 60%–65%: 21 indexed breeds (8%). Above this entry. 65%–70%: 11 indexed breeds (4%). Above this entry. 70%–75%: 15 indexed breeds (5%). Above this entry. 75%–80%: 13 indexed breeds (5%). Above this entry. 80%–85%: 11 indexed breeds (4%). Above this entry. 85%–90%: 12 indexed breeds (4%). Above this entry. 90%–95%: 12 indexed breeds (4%). Above this entry. 95%–100%: 142 indexed breeds (52%). Above this entry. Great Pyrenees 5% 100% every breed with ≥50 FDA reports, bucketed by value

Each bar is a band; taller bars hold more indexed breeds. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source FDA Center for Veterinary Medicine, openFDA adverse event extract (PlainBreed) · July 2026 extract

This histogram uses the same ≥50-report cohort as the highest death-coded share ranking. A higher share means more of this breed's reported events were death-coded, not a mortality rate for living animals.

Great Pyrenees among report-volume vs. death-rate peers

Every breed shown has at least 50 filed reports. Volume reflects how often a breed is reported, not how common it is; death rate is the share of a breed's own reports coded as a death outcome.

Source: FDA openFDA Animal & Veterinary Adverse Events database 2×2 strategic matrix plotting 30 entities by Total Reports (X) and Death Rate (%) (Y), with a crosshair dividing the plot into four quadrants. High volume, high death rateLow volume, high death rateHigh volume, low death rateLow volume, low death rate 020,00040,00060,00080,000100,000 0%5%10%15% Total Reports Death Rate (%) Great Pyrenees vs. all breeds, report volume and death-coded share Retriever - Labrador-93675, 3.7%Crossbred Canine/dog-70591, 3.2%Domestic Shorthair-65226, 7.2%Dog (unknown)-48820, 8.8%Retriever - Golden-35980, 3.7%Shepherd Dog - German-32220, 4.4%Chihuahua-31521, 4.2%Terrier - Yorkshire-24924, 3.7%Shih Tzu-24405, 3.6%Boxer (German Boxer)-19405, 4.4%Beagle-17970, 3.6%Pit Bull-17865, 3.1%Shepherd Dog - Australian-16274, 3.7%Terrier (unspecified)-14058, 3.1%Maltese-13940, 3.2%Dachshund (unspecified)-13512, 4.6%Cat (unknown)-13248, 9.3%Terrier - Jack Russell-10423, 3.7%Collie - Border-10130, 4.3%Siberian Husky-9811, 4.5%Domestic Longhair-9615, 7%Pug-9224, 5.2%Spitz - German Pomeranian-9086, 4.9%Terrier - Bull - American Pit-8769, 4.7%Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog)-7871, 3.6%Terrier - Boston-7737, 4.5%Spaniel - Cocker American-7640, 4%Domestic (unspecified)-7576, 13.4%Poodle (unspecified)-7534, 3.4%Schnauzer - Miniature-7513, 4.4%
Source: FDA openFDA Animal & Veterinary Adverse Events database
Average weight at time of report: 39.7 kg (87.5 lbs)

Top Reported Reactions

Lack of efficacy (endoparasite) - heartworm 930
Vomiting 626
INEFFECTIVE, HEARTWORM LARVAE 316
Lethargy (see also Central nervous system depression in 'Neurological') 245
Diarrhoea 226
Lack of efficacy (endoparasite) - hookworm 226
Lack of efficacy (ectoparasite) - flea 217
Emesis 196
Lack of efficacy - NOS 181
Lack of efficacy (ectoparasite) - tick NOS 173
Lack of efficacy (bacteria) - Borrelia 154
Seizure NOS 140
Underdose 112
Cardiac disorder NOS 101
Panting 98

Most Referenced Drugs

Ivermectin + Pyrantel As Pamoate Salt 838
Milbemycin Oxime + Spinosad 675
Pyrantel Pamoate;Sarolaner 471
Milbemycin Oxime + Praziquantel 402
Moxidectin 400
Afoxolaner 344
Fluralaner 13.64% 12-Week Chew 190
Fluralaner Chew Tablets 140
Melarsomine Dihydrochloride 136
Spinosad 132
Bedinvetmab 131
Carprofen 99
Oclacitinib Maleate 84
Sarolaner 82
Lotilaner 80

Outcome Breakdown

Ongoing
1,531 (35.2%)
Outcome Unknown
1,480 (34.0%)
Recovered/Normal
939 (21.6%)
Recovered with Sequela
231 (5.3%)
Died
93 (2.1%)
Euthanized
77 (1.8%)

Gender Distribution

Male 2,312 (51.2%)
Female 2,106 (46.7%)
Unknown 74 (1.6%)
Mixed 21 (0.5%)

Reports by Year

Year Reports Trend
2010 85
2011 120
2012 149
2013 180
2014 173
2015 174
2016 238
2017 238
2018 261
2019 322
2020 363
2021 365
2022 403
2023 436
2024 489
2025 440
2026 77

Great Pyrenees: low death-coded share in the FDA CVM extract

Signature read: 4,513 reports place Great Pyrenees in the upper third of breed filing volume (#45 of 510). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Great Pyrenees sits at #45 of 510 by report volume among all breeds and #39 of 298 among dog breeds, with 4,513 reports and 170 (3.8%) death-coded. On death-coded share among breeds with ≥50 reports, it ranks #188 of 275. Mean age at report: 3.8 years, average weight 39.7 kg (87.5 lbs).

Top reported signs: Lack of efficacy (endoparasite) - heartworm (930), Vomiting (626), INEFFECTIVE, HEARTWORM LARVAE (316). Most-referenced drug: Ivermectin + Pyrantel As Pamoate Salt (838 reports), followed by Milbemycin Oxime + Spinosad (675) and Pyrantel Pamoate;Sarolaner (471).

Outcome coding on 4,351 status-recorded reports is dominated by Ongoing (35.2%). Annual submissions ranged 77-2,026 across 17 years on file.

Dog Breeds With a Similar Report Volume

Showing 6 of 297 dog breeds in our dataset, ranked by closest report volume.

Nationwide breeds with similar profiles

High-volume peer sets for Great Pyrenees drawn from openFDA outside the Dog family so the neighborhoods are not species containment (the similar-volume list above stays within species).

Similar death-coded share

Nearest other-species breeds with ≥50 reports (3.8% death-coded here).

Similar average weight

Nearest other-species breeds by reported average weight (39.7 kg here).

What to do with this dog

A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.

Frequently Asked Questions

How many FDA adverse event reports involve Great Pyrenees?
There are 4,513 adverse event reports involving Great Pyrenees in the FDA database, of which 170 were death-coded (3.8% of those reports). That is a share of REPORTED events, not a mortality rate for the breed: adverse events reach the FDA when something goes wrong, so the denominator is reports, never the population of animals. According to the same FDA CVM extract, Great Pyrenees ranks #45 of 510 by report volume among all breeds PlainBreed indexes (#39 of 298 among dog breeds).
Where does Great Pyrenees sit among other breeds in PlainBreed's corpus?
According to FDA CVM report volume, Great Pyrenees is #45 of 510 breeds indexed on PlainBreed (same ordering as the most-reported-breeds ranking). Inside Dog, it is #39 of 298. Among breeds with at least 50 reports, its death-coded share ranks #188 of 275 (same cohort as highest-death-rate). These are placement ranks in the reporting corpus, not clinical risk scores.
What are the most common adverse reactions reported for Great Pyrenees?
The most commonly reported adverse reactions for Great Pyrenees are Lack of efficacy (endoparasite) - heartworm (930 reports), Vomiting (626 reports), INEFFECTIVE, HEARTWORM LARVAE (316 reports), Lethargy (see also Central nervous system depression in 'Neurological') (245 reports), Diarrhoea (226 reports).
What drugs are most frequently associated with Great Pyrenees adverse events?
The drugs most frequently referenced in Great Pyrenees adverse event reports are Ivermectin + Pyrantel As Pamoate Salt (838 reports), Milbemycin Oxime + Spinosad (675 reports), Pyrantel Pamoate;Sarolaner (471 reports), Milbemycin Oxime + Praziquantel (402 reports), Moxidectin (400 reports).
What is the average age of Great Pyrenees in adverse event reports?
The average age of Great Pyrenees at the time of adverse event reports is 3.8 years, with an average weight of 39.7 kg (87.5 lbs).

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Great Pyrenees (Dog), extract as of July 2026 extract. 4,513 reports · 170 death-coded (3.8% of reports, not a mortality rate) · #45 of 510 by volume.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →